Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 12 |
| List of Tables | 8 | 3 |
| List of Figures | 11 | 4 |
| Anti-Bacterials Market to 2016 Introduction | 15 | 1 |
| GBI Research Report Guidance | 15 | 1 |
| Anti-Bacterials Market to 2016 Overview | 16 | 10 |
| Bacterial Classification | 16 | 1 |
| Antimicrobial Spectrum | 16 | 1 |
| Bacterial Resistance | 16 | 1 |
| Cephalosporin Antibiotic | 16 | 1 |
| First Generation | 17 | 1 |
| Second Generation | 17 | 1 |
| Third Generation | 18 | 1 |
| Fourth Generation | 18 | 1 |
| Fifth Generation | 18 | 1 |
| Penicillin Antibiotic | 18 | 1 |
| Natural Penicillins | 19 | 1 |
| Penicillinase-Resistant Penicillins | 19 | 1 |
| Aminopenicillins | 19 | 1 |
| Extended Spectrum Penicillins | 19 | 1 |
| Quinolones Antibiotic | 20 | 1 |
| First Generation | 20 | 1 |
| Second Generation | 20 | 1 |
| Third generation | 20 | 1 |
| Fourth generation | 20 | 1 |
| Macrolide Antibiotic | 20 | 1 |
| Antibacterials Market Size | 21 | 1 |
| Antibacterial Market Size by Geography | 22 | 1 |
| Antibacterial Market Size by indication | 23 | 1 |
| Drivers and Barriers for the Antibacterial Market | 24 | 1 |
| Drivers for Antibacterial Market | 24 | 1 |
| Increase in the use of antibiotics | 24 | 1 |
| Drug Resistant Organisms | 24 | 1 |
| Depleting Environmental Conditions | 24 | 1 |
| Barriers for Antibacterial Market | 25 | 1 |
| Self-limiting Nature of the Disease | 25 | 1 |
| Increasing Antimicrobial Resistance | 25 | 1 |
| Patent Expiry of Branded Products | 25 | 1 |
| Weak Pipelines | 25 | 1 |
| Anti-Bacterials Market to 2016 Tuberculosis | 26 | 32 |
| Overview | 26 | 1 |
| Microbiology | 26 | 1 |
| Diagnosis | 26 | 1 |
| Treatment | 26 | 1 |
| Prevention | 27 | 1 |
| Tuberculosis Drugs Market Size | 27 | 1 |
| Tuberculosis Drugs Market Forecast and CAGR | 28 | 5 |
| Drivers and Barriers for Tuberculosis Therapeutics Market | 33 | 1 |
| Drivers for the Tuberculosis Drugs Market | 33 | 1 |
| Increase in Aged Population Increases Tuberculosis Prevalence | 33 | 1 |
| Decrease in Duration of Therapy | 33 | 1 |
| Barriers to Tuberculosis Drugs | 34 | 1 |
| Poor Compliance Rates | 34 | 1 |
| Lower Case Detection Rates | 34 | 1 |
| Affordability | 34 | 1 |
| Availability | 34 | 1 |
| Product Profile of the Major Marketed Products in the Tuberculosis Market | 34 | 1 |
| Isoniazid (INH) | 34 | 1 |
| Overview | 34 | 1 |
| Pricing | 35 | 1 |
| Rifampin (RIF) | 35 | 1 |
| Overview | 35 | 1 |
| Pricing | 35 | 1 |
| Pyrazinamide (PZA) | 35 | 1 |
| Overview | 35 | 1 |
| Pricing | 35 | 1 |
| Ethambutol (EMB) | 36 | 1 |
| Overview | 36 | 1 |
| Pricing | 36 | 1 |
| Kanamycin | 36 | 1 |
| Overview | 36 | 1 |
| Pricing | 36 | 1 |
| Ofloxacin | 36 | 1 |
| Overview | 36 | 1 |
| Pricing | 36 | 1 |
| Ethionamide | 37 | 1 |
| Overview | 37 | 1 |
| Pricing | 37 | 1 |
| Global Tuberculosis Market: Pipeline Analysis | 37 | 1 |
| Overview | 37 | 1 |
| Research and Development Pipeline- Discovery | 38 | 1 |
| Research and Development Pipeline Preclinical | 38 | 1 |
| Ac2SGL Diacylated Sulfoglycolipid | 38 | 1 |
| AdAg85A Vaccine | 38 | 1 |
| ApoVax104-TB Vaccine | 39 | 1 |
| FAS20013 | 39 | 1 |
| HBHA | 39 | 1 |
| HG85 A/B | 39 | 1 |
| HG856A | 39 | 1 |
| HG856-BCG | 39 | 1 |
| HG856-SeV | 39 | 1 |
| HVJ-Envelope/HSP65 DNA + IL-12 DNA | 40 | 1 |
| MTBVAC01 | 40 | 1 |
| NasL3/AM85B | 40 | 1 |
| NasL3/HtkBCG (BCG adjuvant) | 40 | 1 |
| paBCG Vaccine | 40 | 1 |
| PMX-10072 | 40 | 1 |
| r30 | 40 | 1 |
| r32kDa BCG Protein | 41 | 1 |
| rBCG T+B rM. smegmatis T+B | 41 | 1 |
| rBCG(mbtB)30 | 41 | 1 |
| SQ109 + TMC207 | 41 | 1 |
| Streptomyces Live Vector | 41 | 1 |
| VecFlu | 41 | 1 |
| Research and Development Pipeline - Phase I | 42 | 1 |
| Ad5Ag85A | 42 | 1 |
| Ag85B-ESAT-6 + CAF01 | 42 | 1 |
| Ag85B-ESAT-6 Vaccine | 42 | 1 |
| AZD5847 | 42 | 1 |
| FP85A | 42 | 1 |
| FP85A + MVA85A | 42 | 1 |
| PNU-100480 | 43 | 1 |
| rBCG30 | 43 | 1 |
| SQ109 | 43 | 1 |
| Vaccine for Tuberculosis | 43 | 1 |
| VPM1002 | 43 | 1 |
| Research and Development Pipeline - Phase II | 43 | 1 |
| Moxifloxacin + Rifapentine, Avelox + Priftin, Rifapentine + Moxifloxacin + Pyrazinamide + Isoniazid | 43 | 1 |
| AERAS-405, Crucell Ad35, Adenovirus 35, Crucell Ad35/AERAS-402 | 43 | 1 |
| GSK M72 | 44 | 1 |
| Interferon Gamma | 44 | 1 |
| Levofloxacin | 44 | 1 |
| Linezolid | 44 | 1 |
| LL 3858, Sudoterb, INH analogue, LL3858 | 44 | 1 |
| Lopinavir + Ritonavir + NRTIs + Rifampicin | 44 | 1 |
| Metronidazole + Antituberculous Chemotherapy, Metronidazole | 44 | 1 |
| Moxifloxacin | 45 | 1 |
| Mtb72F/AS02, Mtb72F/AS02A TB vaccine | 45 | 1 |
| MVA85A, Recombinant modified vaccinia virus ankara 85A, MVA 85A | 45 | 1 |
| OPC-67683 | 45 | 1 |
| PA-824 | 45 | 1 |
| PA-824 + Pyrazinamide + Moxifloxacin | 45 | 1 |
| PA-824 + Pyrzinamide | 45 | 1 |
| Raltegravir + Tenofovir + Lamivudine | 46 | 1 |
| Recombinant Tuberculosis Vaccine | 46 | 1 |
| Rifabutin + Efavirenz | 46 | 1 |
| Rifabutin + Lopinavir/Ritonavir | 46 | 1 |
| Rifabutin + Nevirapine | 46 | 1 |
| Rifampicin | 46 | 1 |
| Rifapentine | 46 | 1 |
| Rifapentine | 47 | 1 |
| Ritonavir + Indinavir + Rifampicin, IDV/r + Rifampicin | 47 | 1 |
| RUTI | 47 | 1 |
| RUTI + Isoniazid | 47 | 1 |
| SQ109, SQ 109 | 47 | 1 |
| SQ109 + Rifampicin, SQ109 + RIF | 47 | 1 |
| TMC 207, R207910, Bedaquiline, TMC207 | 48 | 1 |
| TMC207 + Pyrazinamide, Bedaquiline + Pyrazinamide | 48 | 1 |
| V-5 Immunitor Vaccine + Anti-Tuberculosis Drugs, V-5 Immunitor Vaccine + ATT | 48 | 1 |
| Zyvox, Linezolid | 48 | 1 |
| Research and Development Pipeline - Phase III | 48 | 1 |
| Abacavir + Lamivudine + Zidovudine | 48 | 1 |
| Cholecalciferol | 49 | 1 |
| Didanosine + Lamivudine + Nevirapine + 2EHRZ3/4RH3 | 49 | 1 |
| Efavirenz + Stavudine + Lamivudine | 49 | 1 |
| Immuvac | 49 | 1 |
| Isoniazid + Cotrimoxazole | 50 | 1 |
| Isoniazid + Ethambutol | 50 | 1 |
| Isoniazid + Rifampin | 50 | 1 |
| Isoniazid + Rifapentine | 50 | 1 |
| Mycobacterium vaccine | 50 | 1 |
| Nevirapine + Rifampicin + Ethambutol + Isoniazid + Pyrazinamid | 50 | 1 |
| Prednisone | 51 | 1 |
| RNTCP Category I Regimen | 51 | 1 |
| Tenofovir + Emtricitabine + Efavirenz | 51 | 1 |
| Global Tuberculosis Market: Strategic Consolidations | 52 | 1 |
| Overview | 52 | 1 |
| Merger and Acquisition Deals | 52 | 1 |
| Deals by Geography | 52 | 1 |
| Deals by Deal Type | 53 | 1 |
| Deals by Year | 53 | 1 |
| Deals by Value ($m) | 54 | 1 |
| Research and Development Licensing Agreements | 55 | 1 |
| Deals by Geography | 55 | 1 |
| Deals by Value | 55 | 1 |
| Deals by Year | 56 | 1 |
| Co-Developments | 56 | 1 |
| Co-Developments by Geography | 56 | 1 |
| Co-Developments by Year | 57 | 1 |
| Anti-Bacterials Market to 2016 Pneumonia | 58 | 28 |
| Overview | 58 | 1 |
| Microbiology | 58 | 1 |
| Diagnosis | 58 | 1 |
| Radiography | 58 | 1 |
| Laboratory Tests | 58 | 1 |
| Treatment | 59 | 1 |
| Prevention | 60 | 1 |
| Pneumonia Drugs Market Size | 60 | 1 |
| Pneumonia Drugs Market Forecast and CAGR | 61 | 9 |
| Drivers and Barriers to Pneumonia Therapeutics Market | 70 | 1 |
| Drivers to Pneumonia Drugs market | 70 | 1 |
| Increase in Diseased Population | 70 | 1 |
| Multi-Drug Resistant Organisms | 70 | 1 |
| Hospital Acquired Pneumonia | 70 | 1 |
| Barriers to Pneumonia Drugs market | 71 | 1 |
| Cost of Therapy | 71 | 1 |
| Weak Pipeline Reduces Market Potential | 71 | 1 |
| Product Profile of the Major Marketed Products in the Pneumonia Market | 71 | 1 |
| Zyvox (linezolid) | 71 | 1 |
| Overview | 71 | 1 |
| Zosyn (piperacillin and tazobactum) | 71 | 1 |
| Overview | 71 | 1 |
| Levaquin (Levofloxacin) | 72 | 1 |
| Overview | 72 | 1 |
| Avelox (moxifloxacin) | 72 | 1 |
| Overview | 72 | 1 |
| Omnicef (cefnidir) | 72 | 1 |
| Overview | 72 | 1 |
| Tygacil (tigecycline) | 72 | 1 |
| Overview | 72 | 1 |
| Doribax (doripenem) | 73 | 1 |
| Overview | 73 | 1 |
| Global Pneumonia Therapeutics Market: Pipeline Assessment | 73 | 1 |
| Overview | 73 | 1 |
| Discovery | 73 | 1 |
| Nasal Pneumococcal Vaccine | 73 | 1 |
| Mimopath Based Pneumococcal Vaccine | 73 | 1 |
| Pre-Clinical | 74 | 1 |
| ACE720 | 74 | 1 |
| Aerucin | 74 | 1 |
| BL-2060 | 74 | 1 |
| LipoNeu | 74 | 1 |
| PAC-G31P | 74 | 1 |
| Panaecin | 74 | 1 |
| Vansolin | 74 | 1 |
| Zysolin | 75 | 1 |
| Phase I | 75 | 1 |
| Chlorhexidine | 75 | 1 |
| GSK1322322 | 75 | 1 |
| GSK2189241A | 75 | 1 |
| NKTR-063 | 75 | 1 |
| Streptococcus Pneumoniae Vaccine | 75 | 1 |
| BC-3781 | 75 | 1 |
| Torezolid | 75 | 1 |
| AZD9742 | 76 | 1 |
| Phase II | 76 | 1 |
| IC43 | 76 | 1 |
| KBPA101 | 76 | 1 |
| Nemonoxacin | 76 | 1 |
| NXL103 | 76 | 1 |
| Radezolid | 76 | 1 |
| Solithromycin | 76 | 1 |
| Amikacin Inhale | 77 | 1 |
| JNJ-32729463 | 77 | 1 |
| GSK2189242A | 77 | 1 |
| 7 Valent Pneumococcal Conjugate Vaccine (7vPCV) | 77 | 1 |
| PB-101 | 77 | 1 |
| Phase III | 77 | 1 |
| Chlorhexidine | 77 | 1 |
| Prednisone | 77 | 1 |